Cargando…
Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer
BACKGROUND: There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC). METHODS: The clinical charts of 233 patients with CRPC treated with enzalutamide were...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486121/ https://www.ncbi.nlm.nih.gov/pubmed/34597353 http://dx.doi.org/10.1371/journal.pone.0258160 |